Burkitt lymphoma

MYC is a gene that helps regulate cell growth. In Burkitt lymphoma, a rearrangement commonly places MYC under an unusually active control region. Diagnosis uses tissue appearance, immune markers and genetic testing to distinguish it from other aggressive B-cell cancers.

The disease can involve lymph nodes, the abdomen, marrow or central nervous system. Epidemiologic patterns differ across endemic, sporadic and immunodeficiency-associated settings. They are not separate predictions of an individual’s outcome.

Burkitt lymphoma develops through genetic changes in B cells. Epstein-Barr virus is strongly associated with endemic disease and some other cases, while immune deficiency can increase risk.

Most EBV infections do not cause lymphoma. The reason a particular person develops Burkitt lymphoma is not always known, and the cancer itself is not contagious.

The lymphoma can enlarge quickly. Depending on the site, symptoms may include abdominal pain or swelling, a facial or jaw mass, enlarged nodes, fever or weight loss.

A large, fast-growing tumor burden can cause tumor lysis syndrome, sometimes even before treatment. Rapid breakdown of cells releases substances that can harm the kidneys and disturb heart rhythm, so prevention and laboratory monitoring are central to care.

Treatment uses prompt multi-drug therapy, commonly with rituximab, and treatment directed at the central nervous system. Regimens are selected according to age, fitness, disease burden and the specialist protocol.

Many patients can achieve lasting remission with initial drug treatment. High-dose treatment followed by stem cell rescue is not a routine addition for someone responding well to first-line therapy.

Relapsed or refractory Burkitt lymphoma is difficult to treat. Salvage chemotherapy, clinical trials and autologous or allogeneic transplantation may be considered for selected responders. The evidence is limited, and results from other large B-cell lymphomas cannot automatically be applied to Burkitt lymphoma.

The beginning of care can be intensive because treatment and prevention of early complications must proceed quickly. Hospital care may include intravenous fluids, close laboratory checks, transfusions and infection management.

CNS-directed procedures and repeated drug cycles can affect daily routines and nutrition. After treatment, follow-up and support for physical recovery, school or work are tailored to the person’s age and treatment exposures.

Most newly diagnosed patients do not need a registry donor. Autologous rescue uses a patient’s own collected stem cells.

An allogeneic transplant requires donated blood-forming cells and may be considered in selected relapsed disease. Relatives, unrelated registry volunteers and other graft options are assessed by the transplant team. Joining a registry supports patients who reach that pathway, without making donor transplantation a promise of rescue for every relapse.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?